These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35186246)

  • 1. A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated von Willebrand disease type 2B patient.
    Casari C; Favier R; Legendre P; Kauskot A; Adam F; Picard V; Lenting PT; Denis CV; Proulle V
    Ther Adv Hematol; 2022; 13():20406207221076812. PubMed ID: 35186246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage.
    Espitia O; Ternisien C; Agard C; Boisseau P; Denis CV; Fouassier M
    Platelets; 2017 Jul; 28(5):518-520. PubMed ID: 27885890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.
    Casari C; Paul DS; Susen S; Lavenu-Bombled C; Harroche A; Piatt R; Poe KO; Lee RH; Bryckaert M; Christophe OD; Lenting PJ; Denis CV; Bergmeier W
    Blood Adv; 2018 Jun; 2(12):1417-1428. PubMed ID: 29925524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential diagnosis of neonatal alloimmune thrombocytopenia: Type 2B von Willebrand disease.
    Penel-Page M; Meunier S; Fretigny M; Le Quellec S; Boisseau P; Vinciguerra C; Ternisien C; Rugeri L
    Platelets; 2017 Dec; 28(8):825-828. PubMed ID: 28436749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.
    Dupont A; Soukaseum C; Cheptou M; Adam F; Nipoti T; Lourenco-Rodrigues MD; Legendre P; Proulle V; Rauch A; Kawecki C; Bryckaert M; Rosa JP; Paris C; Ternisien C; Boisseau P; Goudemand J; Borgel D; Lasne D; Maurice P; Lenting PJ; Denis CV; Susen S; Kauskot A
    Haematologica; 2019 Dec; 104(12):2493-2500. PubMed ID: 30819911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.
    Casari C; Berrou E; Lebret M; Adam F; Kauskot A; Bobe R; Desconclois C; Fressinaud E; Christophe OD; Lenting PJ; Rosa JP; Denis CV; Bryckaert M
    J Clin Invest; 2013 Dec; 123(12):5071-81. PubMed ID: 24270421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
    Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
    Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M.
    Berrou E; Kauskot A; Adam F; Harel A; Legendre P; Lavenu Bombled C; Rothschild C; Prevost N; Christophe OD; Lenting PJ; Denis CV; Rosa JP; Bryckaert M
    PLoS One; 2015; 10(12):e0143896. PubMed ID: 26645283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions.
    Golder M; Pruss CM; Hegadorn C; Mewburn J; Laverty K; Sponagle K; Lillicrap D
    Blood; 2010 Jun; 115(23):4862-9. PubMed ID: 20371742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Type 2B von Willebrand Disease during Pregnancy.
    McLaughlin D; Kerr R
    Acta Haematol; 2017; 137(2):89-92. PubMed ID: 28118618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudo (platelet-type) von Willebrand disease in pregnancy: a case report.
    Grover N; Boama V; Chou MR
    BMC Pregnancy Childbirth; 2013 Jan; 13():16. PubMed ID: 23327637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic Parameters in Genotypically Selected Type 2B von Willebrand Disease Patients: A Large, Single-Center Experience Including a New Novel Mutation.
    Woods AI; Kempfer AC; Paiva J; Sanchez-Luceros A; Bermejo E; Chuit R; Alberto MF; Blanco AN; Lazzari MA
    Semin Thromb Hemost; 2017 Feb; 43(1):92-100. PubMed ID: 27978591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
    Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
    Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B.
    Nurden P; Gobbi G; Nurden A; Enouf J; Youlyouz-Marfak I; Carubbi C; La Marca S; Punzo M; Baronciani L; De Marco L; Vitale M; Federici AB
    Blood; 2010 Apr; 115(13):2649-56. PubMed ID: 20118404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.
    Federici AB; Mannucci PM; Castaman G; Baronciani L; Bucciarelli P; Canciani MT; Pecci A; Lenting PJ; De Groot PG
    Blood; 2009 Jan; 113(3):526-34. PubMed ID: 18805962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.
    Adam F; Casari C; Prévost N; Kauskot A; Loubière C; Legendre P; Repérant C; Baruch D; Rosa JP; Bryckaert M; de Groot PG; Christophe OD; Lenting PJ; Denis CV
    Sci Rep; 2016 May; 6():26306. PubMed ID: 27212476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation.
    Jackson SC; Sinclair GD; Cloutier S; Duan Z; Rand ML; Poon MC
    Blood; 2009 Apr; 113(14):3348-51. PubMed ID: 19060241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired von Willebrand syndrome with a type 2B phenotype: diagnostic and therapeutic dilemmas.
    Scepansky E; Othman M; Smith H
    Acta Haematol; 2014; 131(4):213-7. PubMed ID: 24296552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
    Jilma-Stohlawetz P; Knöbl P; Gilbert JC; Jilma B
    Thromb Haemost; 2012 Aug; 108(2):284-90. PubMed ID: 22740102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of type 2b von Willebrand disease in the neonatal period.
    Proud L; Ritchey AK
    Pediatr Blood Cancer; 2017 Jan; 64(1):103-105. PubMed ID: 27468167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.